Executive summary
Private equity ownership compresses a decade of operating pressure into a five-year hold, and the leaders at the center of that pressure churn at extraordinary rates. More than seven in ten PE-backed CEOs are replaced during the hold, much of it unplanned, and each forced transition lengthens the hold and erodes returns. Beneath the turnover statistics sits a population of founders and executives carrying a documented mental-health load that the deal model rarely accounts for. This report treats portfolio leadership strain as both a value-creation risk and a clinical one.
Aggressive value-creation timelines, board scrutiny, 100-day plans, and the personal financial stakes of an exit produce intense, concealed strain in the leaders a sponsor most needs to perform.
Portfolio-company benefit programs and insurance-based referrals carry a visibility cost that a watched CEO will not pay, so the leaders under the most pressure are the least likely to use them.
What works is confidential, private-pay, senior-clinician care calibrated to the pace and exposure of PE ownership, accessed before strain becomes a costly transition.
Sponsors who make discreet clinical support genuinely available protect leadership continuity, decision quality, and the value-creation timeline that unplanned churn otherwise destroys.
The problemThe leaders a deal depends on are also the ones most likely to break.
More than 70% of PE-backed CEOs are replaced during a hold period that now averages roughly five to six years, according to a survey of 518 PE-backed chief executives.1 Academic work reaches the same place: in a study of 193 large buyouts, 71% installed a new CEO under private equity ownership.4 Much of this churn is not planned. In one industry survey, 34% of portfolio-company CEO turnover was unplanned, and 83% of PE executives said unplanned CEO turnover lengthens hold periods while 46% said it erodes returns.6,7
The usual framing treats leadership churn as a talent-upgrade problem: replace the founder, install a professional operator, drive the plan. It misses that the people inside this machine are under measurable strain, and that the strain is rarely addressed before it becomes a transition. Founders carry it most acutely: in a peer-reviewed study, mental-health differences directly or indirectly affected 72% of entrepreneurs, yet in a separate founder survey 72% reported their business directly affecting their mental health while only 23% had sought professional support.12,13 When the single most value-relevant asset in a portfolio company is the judgment of one or two strained leaders, the gap between turnover as strategy and turnover as breakdown is where deal value quietly leaks.
In private equity, leadership is the asset that creates the value and the asset most likely to fail under the pressure of creating it. CEREVITY Clinical Whitepaper, Series No. 41
The evidenceWhat the research shows
Four numbers frame the scale of the problem: how often PE-backed leaders are replaced, how much that turnover lengthens a hold, the documented clinical load on founders, and the size of the research base behind these claims. Each is drawn from a named, dated source.
70%+
of PE-backed CEOs are replaced during the hold period, much of it unplanned.
Heidrick & Struggles, 2024
83%
of PE executives say unplanned CEO turnover lengthens the hold period.
AlixPartners, 2018
71%
of large buyouts install a new CEO under private equity ownership.
Gompers, Kaplan & Mukharlyamov / NBER, 2022
242
entrepreneurs in the peer-reviewed study documenting elevated psychiatric prevalence.
Freeman et al., 2019
Read together, these figures describe a model that depends on leadership and routinely loses it. PE-backed CEOs are replaced at rates that dwarf public-company norms, a large share unplanned; that turnover demonstrably lengthens holds and reduces returns; and the founders and executives at the center carry an unusually high clinical burden that the deal thesis seldom names. The churn is usually read as portfolio management. The evidence says a meaningful part of it is strain that was never addressed, and that addressing it earlier is cheaper than replacing a leader and resetting a value-creation plan.
| Metric | Figure | Population / scope | Source, Year |
|---|---|---|---|
| PE-backed CEOs replaced during hold | Over 70% | n=518 CEOs | Heidrick & Struggles, 2024 |
| Large buyouts installing a new CEO | 71% | n=193 buyouts | NBER w30899, 2022 |
| Portfolio CEO turnover that is unplanned | 34% | PE survey | AlixPartners & Vardis, 2018 |
| PE execs saying unplanned turnover lengthens holds | 83% | PE executives | AlixPartners, 2018 |
| PE firms saying unplanned turnover erodes returns | 46% | PE firms | AlixPartners, 2018 |
| Executive replacement cost | 200% to 400% of salary | Executive roles | SHRM |
| Entrepreneurs affected by mental-health differences | 72% | n=242 | Freeman et al., 2019 |
The frameworkA model you can name and own
A named model gives a deal team and a portfolio leader a shared way to talk about something the deal model usually only registers as a line in an exit post-mortem. Leadership strain under PE ownership is not a single event; it moves through phases tied to the rhythm of the hold, and each phase offers a different, cheaper point of intervention than the one that follows. The model below traces how a portfolio leader moves from the energy of close toward churn. The phases are clinical observations made general, not a diagnosis of any one leader.
CEREVITY model
The Hold-Period Strain Cycle
A four-phase description of how leadership strain develops over a private equity hold in operators whose competence hides it. The stronger the leader, the later the decline becomes visible, and the more expensive it is by the time it shows. Each phase names a pattern a deal partner, a board member, or the leader themselves can recognize.
Acceleration
The 100-day plan and value-creation targets land at once. The leader meets them by spending personal reserves first, trading recovery for pace, before any metric in the model moves.
Performance
The strain is managed in private. A CEO who cannot show fatigue to a watchful board becomes expert at appearing fine in every monthly review, which delays their own recognition as much as the sponsor's.
Friction
Sleep, judgment, and board relationships degrade in sequence. Targets are still defended, but at rising personal cost, and quiet friction with the sponsor begins to surface.
Churn
A threshold is crossed and the leader is replaced or leaves. By this point the firm is managing a transition, a lengthened hold, and a value-creation reset rather than a treatable strain, and the cost is at its highest.
The decision the model asks of a sponsor is where it wants to meet its leaders. At Acceleration, a confidential conversation can protect both the person and the plan. At Churn, the firm is absorbing replacement cost, a lengthened hold, and a value-creation reset that the original underwriting did not price. Earlier recognition is the entire point.
By professionHow it presents across roles
Strain under private equity ownership does not look the same across the leadership of a portfolio company. A founder who sold the business they built carries a different load than a professional CEO parachuted in by the sponsor, which differs again from the CFOs and COOs upgraded mid-hold. The three groups below show how the same strain cycle presents differently depending on the seat.
Founder-CEOs under new ownership
Founders who sell to private equity face a uniquely difficult transition: they retain operational responsibility while losing ultimate control, and their identity is fused with a company that now answers to a board. The clinical baseline is already elevated. In a peer-reviewed study of 242 entrepreneurs, 49% reported a lifetime mental-health condition, including 30% reporting depression, and 72% reported that mental-health differences had directly or indirectly affected them.12 Founder surveys reinforce the pattern: 72% reported their business directly impacting their mental health, 37% reported anxiety and 36% burnout, yet only 23% had sought professional support and as few as 7% had accessed mental-health help.13,14 At network level, the clinical observation is that founder-CEOs live in the Acceleration and Performance phases for a very long time, because showing strain to a new owner feels like admitting the thesis was wrong. The sponsor inherits a leader who is both the most knowledgeable person in the building and the one carrying the most concealed load. When that leader churns, the deal loses founder knowledge, customer relationships, and cultural continuity at once. This is the group for whom confidential support reachable before the Churn phase has the highest leverage, because the strained person is also the deal's single largest source of value at risk.
Hired professional CEOs
Professional CEOs installed by the sponsor face a different but equally intense pressure. They arrive as outsiders, are judged on a quarterly cadence against an aggressive plan, and are expected to project total command from day one. The numbers describe high churn: in large buyouts, 71% installed a new CEO, of whom roughly three quarters were external hires and two thirds complete outsiders, and across PE-backed companies CEO exits cluster one to two years after the transaction.4 Median PE-backed CEO total compensation sits near $752,000, and a notable share receive no equity, which sharpens the personal stakes of hitting or missing the plan.1 For this group the clinical pattern is heavy time in the Performance phase, because the role rewards visible composure above all. The cost of losing them is steep and compounding. Executive replacement runs from 200% to 400% of annual salary, and over 40% of executive hires fail within 18 months, so a sponsor that churns one professional CEO frequently churns the next as well.15 The strain that precedes each transition is usually invisible to the board that will pay to replace the leader and reset the timeline once more.
Portfolio CFOs and COOs
The CFO is the most frequently upgraded seat after a buyout, and the broader portfolio C-suite churns close behind. Roughly 60% of companies replace their CFO after acquisition, and at the largest sponsors a substantial share of portfolio companies cycle through three or more CFOs within the first five years of ownership.10,11 These leaders carry the operational weight of the value-creation plan, translating sponsor expectations into execution while managing teams below them, often without the protection or visibility of the CEO seat. At network level the clinical observation is that portfolio CFOs and COOs spend long stretches in the Acceleration and Friction phases, absorbing pressure from the sponsor above and the organization below during exactly the periods, diligence, integration, and exit preparation, when the load is heaviest. Their departures are easy to underestimate because each is less visible than a CEO change, but collectively they drive a large share of portfolio leadership turnover and institutional-knowledge loss. Supporting this layer is where a sponsor can protect the most leaders for the least cost, and where early, confidential intervention pays back fastest across a portfolio.
The stakesThe cost of inaction
A sponsor measures the cost of leadership strain in three ledgers: the direct cost of replacing leaders who churn, the value-creation drag of a lengthened hold, and the second-order damage to founder judgment and decision quality. The largest line is rarely the one on the search firm's invoice.
Leadership turnover and replacement
The direct cost of replacing an executive runs from 200% to 400% of annual salary once search, onboarding, and lost momentum are counted, and over 40% of executive hires fail within 18 months, so the cost frequently recurs.15 At the CEO level the stakes are vivid: in one widely reported case a company that cycled through four CEOs in five years paid an incoming chief executive a package valued near $96 million.15 Every one of these dollars is spent reacting to a transition that earlier intervention might have prevented.
Value-creation disruption and hold-period drag
The replacement invoice is the smaller number. Unplanned leadership churn directly attacks the deal thesis: 83% of PE executives said it lengthens hold periods and 46% said it reduces returns, while investors broadly identify a weak leadership team as a top driver of disappointing exits.6,7,10 Hold periods are already stretching, with the median U.S. buyout hold reaching 3.4 years and a growing share of companies held five years or more, so any leadership-driven delay compounds against a clock that is already running long.16 A reset value-creation plan can cost a fund far more than the leader it replaced.
Founder health and decision quality
The least visible cost is the most consequential: strain degrades the judgment that the entire thesis rests on. Founders report their business directly affecting their mental health 72% of the time, yet only a small minority seek support, and roughly half of CEOs report chronic loneliness.13 A single degraded decision by a strained leader, on a deal, a hire, or a customer, can cost a portfolio company more than years of clinical support for its entire leadership team. Protecting decision quality is the highest-leverage and least-measured return available to a sponsor.
The solutionWhat effective care looks like
Good care for portfolio leaders has to clear three bars that standard programs do not. It must be genuinely confidential, because a CEO under board and investor scrutiny will not risk a record that could surface in diligence or unsettle a sponsor. It must be delivered by clinicians who understand the pace of a hold, the exposure of a watched leader, and the personal stakes of an exit, so the leader does not spend the first month explaining their world. And it must be reachable before strain becomes a transition, on a schedule that bends around a board calendar and a deal timeline rather than the reverse. Anything that fails one of these bars is a benefit a sponsor can list and no leader will use.
CEREVITY is built around those bars. It is a nationwide network of independent licensed clinicians, matched to the person rather than assigned by a panel, delivered by secure video, on a private-pay basis that keeps the work confidential and outside any insurance, employer, or portfolio record. Sessions run in three formats: a 50-minute standard session, a 90-minute extended session, and a 3-hour intensive for periods of acute load such as integration or exit preparation. The model is designed for exactly the leader who would never use a company program, and to be reachable while strain is still in the Acceleration phase rather than at Churn.
ImplementationHow to put it into practice
A sponsor cannot mandate that its portfolio leaders protect their mental health, and should not try. What it can do is treat leadership continuity as the value-creation asset it is and remove every barrier between a strained leader and confidential help. The four steps below are a practical sequence a fund can run across a portfolio.
- 01
Build confidential access into the platform
Offer a private-pay clinical resource that sits entirely outside the portfolio company's HR file, insurance record, and any sponsor visibility. No diagnosis code, no shared chart, no diligence trail. For watched leaders the fear of a record is the single largest barrier, and removing it is the precondition for everything else.
- 02
Introduce it at close, not at crisis
Make support a standard part of the post-close operating toolkit, framed alongside operating partners and executive coaching rather than as a remedy for a struggling leader. Introduced during the Acceleration phase, it becomes ordinary infrastructure; introduced at Churn, it arrives too late to change the outcome.
- 03
Match intervention to the phase
Use the Hold-Period Strain Cycle as a shared language between deal teams and portfolio boards. Build moments in board reviews and value-creation check-ins where Acceleration and Performance strain can be named early, rather than waiting for the Friction and Churn phases when only a search remains.
- 04
Measure continuity, not utilization
Judge the program across the portfolio by leadership retention, succession stability, and hold-period predictability, not by session counts. Confidential care produces no usage report by design, so the right metrics are CEO and C-suite continuity and the cost of unplanned transitions avoided, tracked against the fund's own churn baseline.
RecommendationsWhere to start
Clinical
Treat leadership strain as deal risk
Underwriting accounts for leverage and market risk but rarely for the strain on the people executing the plan. Build confidential, clinically informed pathways that can surface burnout, depression, and anxiety, which the evidence shows affect a majority of founders, before they present as an unplanned transition.12,13
Clinical
Offer care portfolio leaders will actually use
Provide a private-pay, confidential clinical option delivered by senior clinicians who understand PE ownership. The single non-negotiable is that it leaves no record a leader has to worry about in diligence or with the board, because that fear is what keeps the highest-stakes leaders away from every existing program.
Structural
Price churn into the value-creation plan
Quantify leadership churn the way you quantify any other risk to return. With more than 70% of PE-backed CEOs replaced during the hold and 83% of PE executives saying unplanned turnover lengthens it, the case for funding prevention is already made.1,6
Structural
Protect the timeline by protecting the leader
A lengthened hold is the most expensive outcome of leadership strain, and the most preventable. Investing in discreet clinical support before the Churn phase is materially cheaper than replacing a CEO, resetting the plan, and absorbing the return erosion that the data attributes to unplanned turnover.6,7
FAQCommon questions
Is PE-backed CEO turnover really about strain, or just talent upgrades?
Why will portfolio CEOs not use the support programs already available?
What does one unplanned leadership transition actually cost a deal?
How does private-pay billing work?
How is my privacy protected?
MethodologyHow this paper was built
Methodology
This report synthesizes peer-reviewed research, executive-search and consulting surveys, academic working papers, and founder-wellbeing studies published between 2017 and 2026. Sources were identified through searches of the NBER working-paper series, Google Scholar, and SpringerLink for private equity leadership, CEO turnover, and entrepreneur psychiatric prevalence, and through the published research of Heidrick & Struggles, AlixPartners and Vardis, Bain & Company, Russell Reynolds, PitchBook, SHRM, and Startup Snapshot for churn, value-impact, and cost data. The leadership-churn figures rest on two complementary sources: the Heidrick & Struggles 2024 PE-Backed CEO Compensation Survey of 518 chief executives, which reports that more than 70% of PE-backed CEOs are replaced during the hold, and Gompers, Kaplan and Mukharlyamov (NBER Working Paper 30899, 2022), a study of 193 large buyouts finding 71% install a new CEO. Value-impact figures, including the 83% lengthens-holds and 46% erodes-returns findings, derive from the AlixPartners and Vardis private equity leadership surveys. Hold-period data derives from PitchBook (2024). Founder mental-health figures derive from Freeman and colleagues (2019), a peer-reviewed study of 242 entrepreneurs published in Small Business Economics, and from the Startup Snapshot 2023 founder survey. Executive-replacement cost ranges derive from SHRM. Several limitations apply. Industry and consulting surveys use proprietary samples and are reported in part through secondary summaries; figures such as the over-70% replacement rate and the 200% to 400% replacement-cost range should be read as well-sourced estimates rather than audited accounting. The widely circulated 73% CEO-replacement statistic is not cleanly traceable to a single source, so this report uses the defensible over-70% (Heidrick) and 71% (NBER) figures instead. The AlixPartners unplanned-turnover figure appears as 34% in some coverage and higher in others; the conservative 34% is used here. Founder-prevalence figures rely on self-report and screening, not clinical diagnosis, and burnout in DSM-5-TR is described in relation to occupational stress rather than as a standalone disorder. Where a multiplier is derived from two figures, it is presented as illustrative. No CEREVITY internal client data is used in this report. CEREVITY is a nationwide network of independent licensed clinicians; nothing here constitutes medical advice or a substitute for care from a licensed clinician. Every external statistic carries a numbered citation tied to the reference list below.
References
- 01[Author. (Year). Title. Publication. URL.]
- 02[Reference 2. Every external statistic above ties to a number here.]
- 03[Reference 3]
- 04[Reference 4]
- 05[Reference 5 ... continue to 15 to 20 total]
Benjamin Rosen, PsyD
PsyD, Licensed Psychologist · Licensed Psychologist
Dr. Rosen is a Licensed Psychologist working with high-achieving professionals across executive, entrepreneurial, legal, and medical fields. His work integrates evidence-based cognitive and psychodynamic approaches with a deep understanding of the pressures that come with sustained responsibility. He sees clients via CEREVITY's nationwide telehealth network.
Talk to someone who gets it.
If this paper describes something you recognize, a confidential conversation is the next step. CEREVITY matches you to an independent licensed clinician who works with people in your position.
Schedule consultationPrivate-pay, telehealth, nationwide. Questions: (562) 295-6650
